NeoGenomics has introduced PanTracer Tissue, a next-generation solid tumour profiling assay, alongside PanTracer Tissue + HRD, to enhance cancer diagnostics.
The new assays aim to provide faster, actionable insights into cancer care, enabling physicians to make informed treatment decisions with greater confidence.
PanTracer Tissue is designed to assess over 500 cancer-related genes, aligning with clinical guidelines and covering essential biomarkers for therapy selection.
The assay requires minimal specimen and can deliver results within eight days, facilitating rapid initiation of treatment strategies.
It builds on NeoGenomics’ tissue-based CGP platform, previously known as NeoComprehensive Solid Tumor.
NeoGenomics president and chief operating officer Warren Stone said: “With PanTracer Tissue and PanTracer Tissue + HRD we’re unlocking a more complete genomic view from a single sample, giving physicians clearer answers, sooner.
“With the addition of PanTracer Tissue + HRD, we are expanding our portfolio to address the unmet need for ovarian cancer therapy selection with the objective of improving patient care.”
The PanTracer Tissue + HRD option enhances tumour profiling by integrating homologous recombination deficiency analysis, particularly for ovarian cancer.
It includes BRCA mutation status and a genomic instability score, which are critical for guiding the use of PARP inhibitors and other DNA repair-targeting therapies.
The combined approach streamlines the testing process and reduces the time to obtain actionable results.
The two assays are part of NeoGenomics’ extensive precision oncology portfolio, aimed at improving patient outcomes through high-quality, guideline-aligned testing.
Based in Fort Myers, Florida, NeoGenomics is a cancer diagnostics company specialising in cancer genetics testing and information services.
It offers a comprehensive oncology-focused testing menu, serving oncologists, pathologists, hospital systems, academic centres, and pharmaceutical firms.
The company operates a network of CAP-accredited and CLIA-certified laboratories across the US and a CAP-accredited laboratory in Cambridge, UK.
